Stoke Therapeutics (NASDAQ:STOK) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Stoke Therapeutics (NASDAQ:STOK) from a hold rating to a buy rating in a research note issued to investors on Tuesday, Zacks.com reports. They currently have $30.00 price objective on the stock.

According to Zacks, “Stoke Therapeutics Inc. is a biopharmaceutical company. It develops antisense oligonucleotide medicines to treat genetic diseases. The company’s product candidate consists of STK-001 which is to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics Inc. is based in Bedford, Massachusetts. “

A number of other analysts also recently issued reports on the company. Canaccord Genuity initiated coverage on Stoke Therapeutics in a research report on Monday, July 15th. They issued a buy rating and a $44.00 target price on the stock. Cowen reaffirmed a buy rating on shares of Stoke Therapeutics in a research report on Thursday, August 15th. JPMorgan Chase & Co. initiated coverage on Stoke Therapeutics in a research report on Monday, July 15th. They issued an overweight rating and a $34.00 target price on the stock. Finally, Credit Suisse Group initiated coverage on Stoke Therapeutics in a research report on Monday, July 15th. They issued an outperform rating and a $35.00 target price on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $35.75.

NASDAQ:STOK opened at $23.11 on Tuesday. The firm has a 50-day moving average of $30.54. Stoke Therapeutics has a 52-week low of $21.26 and a 52-week high of $39.04.

Stoke Therapeutics (NASDAQ:STOK) last released its earnings results on Wednesday, August 14th. The company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.58). Research analysts expect that Stoke Therapeutics will post -2.23 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the stock. Platinum Investment Management Ltd. bought a new position in Stoke Therapeutics during the second quarter worth about $29,000. Victory Capital Management Inc. bought a new position in Stoke Therapeutics during the second quarter worth about $73,000. Ladenburg Thalmann Financial Services Inc. bought a new position in Stoke Therapeutics during the second quarter worth about $88,000. Morgan Stanley bought a new position in Stoke Therapeutics during the second quarter worth about $104,000. Finally, KCL Capital L.P. bought a new position in Stoke Therapeutics during the second quarter worth about $292,000. Institutional investors and hedge funds own 43.43% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

See Also: Fundamental Analysis

Get a free copy of the Zacks research report on Stoke Therapeutics (STOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.